Compare drug alternatives
Steglujan® Alternatives
Steglujan®(ertugliflozin / sitagliptin) | Trijardy®(empagliflozin / linagliptin / metformin) |
---|---|
Prescription Only | Prescription Only |
Dosage & Administration | |
Administration | |
Oral . Learn more. | Oral . Learn more. |
Dosing | |
Recommended starting dose is 5 mg ertugliflozin/100 mg sitagliptin once daily, taken in the morning, with or without food. Increase dose to 15 mg ertugliflozin/100 mg sitagliptin once daily in those tolerating STEGLUJAN for additional glycemic control. . Learn more. | The maximum recommended dose of TRIJARDY XR is 25 mg empagliflozin, 5 mg linagliptin and 2000 mg metformin HCl. Take once daily with a meal in the morning. Swallow whole; do not split, crush, dissolve, or chew.. Learn more. |
Latin Shorthand | |
5 mg ertugliflozin/100 mg sitagliptin qd in AM, with or without food. Increase to 15 mg ertugliflozin/100 mg sitagliptin qd for those tolerating STEGLUJAN and needing additional glycemic control.. Learn more. | Max dose TRIJARDY XR: 25 mg empagliflozin, 5 mg linagliptin, 2000 mg metformin HCl. Take 1x daily with AM meal. Swallow whole; no splitting, crushing, dissolving, or chewing.. Learn more. |
Financial Assistance | |
Out-Of-Pocket Costs With Copay Card | |
$0. Learn more. | $10. Learn more. |
Annual Cap | |
$583 per fill . Learn more. | $175 per month. Learn more. |
Assistance Expiration | |
12 uses. Learn more. | 12/31/23. Learn more. |
Generics | |
No lower-cost generic available | No lower-cost generic available |
Physician Advisory | |
Adverse Reactions | |
Most common adverse reactions associated with ertugliflozin
(incidence ≥5%): female genital mycotic infections.
Most common adverse reactions associated with sitagliptin
(incidence ≥5%): upper respiratory tract infection, nasopharyngitis
and headache. In the add-on to sulfonylurea and add-on to insulin
studies, hypoglycemia was also more commonly reported in patients
treated with sitagliptin compared to placebo.. Learn more. | Most common adverse reactions (5% or greater incidence) were upper
respiratory tract infection, urinary tract infection, nasopharyngitis, diarrhea,
constipation, headache, and gastroenteritis. . Learn more. |
Mechanism of Actions (MoA) | |
SGLT2 Inhibitors. Learn more. | SGLT2 Inhibitors. Learn more. |
Special Populations | |
Popular Alternatives
- Steglujan® vs Victoza
- Steglujan® vs Trulicity
- Steglujan® vs Skyclarys
- Steglujan® vs Skyclarys
- Steglujan® vs Ozempic
- Steglujan® vs Rybelsus
- Steglujan® vs Mounjaro
- Steglujan® vs Bydureon®
- Steglujan® vs Invokamet XR
- Steglujan® vs Invokamet
- Steglujan® vs Invokana
- Steglujan® vs Farxiga
- Steglujan® vs Glyxambi
- Steglujan® vs Jardiance
- Steglujan® vs Synjardy
- Steglujan® vs Segluromet
- Steglujan® vs Steglatro
- Steglujan® vs Inpefa